These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2644746)

  • 1. Treatment with active vitamin D (alphacalcidol) in patients with mild primary hyperparathyroidism.
    Lind L; Wengle B; Sørensen OH; Wide L; Akerström G; Ljunghall S
    Acta Endocrinol (Copenh); 1989 Feb; 120(2):250-6. PubMed ID: 2644746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension in primary hyperparathyroidism--reduction of blood pressure by long-term treatment with vitamin D (alphacalcidol). A double-blind, placebo-controlled study.
    Lind L; Wengle B; Wide L; Sörensen OH; Ljunghall S
    Am J Hypertens; 1988 Oct; 1(4 Pt 1):397-402. PubMed ID: 3063290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects on serum parathyroid hormone of intravenous treatment with alphacalcidol in patients on chronic hemodialysis.
    Ljunghall S; Althoff P; Fellström B; Marjanovic B; Nisell J; Weiss L; Wide L
    Nephron; 1990; 55(4):380-5. PubMed ID: 2392190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of 1,25-(OH)2-vitamin D are not altered by long-term supplementation with alphacalcidol (1-OH-vitamin D3). A double-blind, placebo-controlled study.
    Lind L; Wengle B; Sörensen OH; Ljunghall S
    Exp Clin Endocrinol; 1992; 99(3):151-3. PubMed ID: 1526265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.
    Brandi L; Daugaard H; Tvedegaard E; Storm T; Olgaard K
    Nephron; 1989; 53(3):194-200. PubMed ID: 2797340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oral pulsatile therapy with active vitamin D3 metabolites--an efficient method of parathyroid hormone synthesis suppression in uremic patients with severe hyperparathyroidism. A pilot study].
    Matuszkiewicz-Rowińska J; Niemczyk S; Bogdańska-Straszyńska B; Ostrowski K
    Pol Arch Med Wewn; 1993 Feb; 89(2):95-101. PubMed ID: 8502602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma ionized calcium and cardiovascular risk factors in mild primary hyperparathyroidism: effects of long-term treatment with active vitamin D (alphacalcidol).
    Lind L; Wengle B; Lithell H; Ljunghall S
    J Intern Med; 1992 Apr; 231(4):427-32. PubMed ID: 1588270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
    Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
    Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alphacalcidol oral pulses are effective in secondary hyperparathyroidism prior to dialysis.
    Koskimies O; Ala-Houhala M
    Clin Nephrol; 1996 Jul; 46(1):70-1. PubMed ID: 8832157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of effect of 24,25-dihydroxyvitamin D3 in primary hyperparathyroidism.
    Netelenbos JC; Asscheman H; Lips P; Van der Vijgh WJ; Jongen MJ; Van Ginkel F; Hackeng WH
    J Clin Endocrinol Metab; 1986 Jul; 63(1):246-8. PubMed ID: 3486877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure].
    Matuszkiewicz-Rowińska J; Niemczyk S; Pacocha E; Puka J; Switalski M; Bogdańska-Straszyńska B; Ostrowski K
    Pol Arch Med Wewn; 1996 Jul; 96(1):15-22. PubMed ID: 8966141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
    Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A
    Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction in serum alkaline phosphatase levels by treatment with active vitamin D (alphacalcidol) in primary and secondary hyperparathyroidism and in euparathyroid individuals.
    Lind L; Wengle B; Lithell H; Ljunghall S
    Scand J Urol Nephrol; 1991; 25(3):233-6. PubMed ID: 1947853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study.
    Lind L; Wengle B; Wide L; Ljunghall S
    Am J Hypertens; 1989 Jan; 2(1):20-5. PubMed ID: 2643969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.
    Fournier A; Morinière PH; Oprisiu R; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B
    Nephron; 1995; 71(3):254-83. PubMed ID: 8569975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of secondary hyperparathyroidism with intermittent oral high doses of 1-alpha-OHD3 plus pharmacological dose of 24,25(OH)2D3.
    Djukanović L; Pejanović S; Dragojlović Z; Stosović M
    Ren Fail; 1994 Nov; 16(6):715-23. PubMed ID: 7899583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrate-product relation of 1-hydroxylase activity in primary hyperparathyroidism.
    LoCascio V; Adami S; Galvanini G; Ferrari M; Cominacini L; Tartarotti D
    N Engl J Med; 1985 Oct; 313(18):1123-5. PubMed ID: 3840228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
    Akiba T; Marumo F; Owada A; Kurihara S; Inoue A; Chida Y; Ando R; Shinoda T; Ishida Y; Ohashi Y
    Am J Kidney Dis; 1998 Aug; 32(2):238-46. PubMed ID: 9708607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease.
    Tarrass F; Yazidi A; Sif H; Zamd M; Benghanem MG; Ramdani B
    Clin Nephrol; 2006 Jun; 65(6):415-8. PubMed ID: 16792136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.